German Biosimilar Substitution Law Could Lead To Tendering
A new law in Germany could lead to tendering in the biosimilars space.
You may also be interested in...
French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.
Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning.
A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.